Navigation Links
New research provides breakthrough in understanding common cancer
Date:6/8/2011

Researchers from the University of Sheffield have discovered valuable insight into how people develop B-cell lymphoma, one of the most common cancers in the UK.

The team, from the University's Institute for Cancer Studies and funded by Leukaemia and Lymphoma Research, Biotechnology and Biological Sciences Research Council (BBSRC) and Yorkshire Cancer Research, found that a mechanism different to that previously thought to be the cause of lymphoma may be responsible for the development of the disease.

Lymphoma is a type of cancer that affects the blood, originating in the lymph glands. B-cells are the immune cells in the human body that are responsible for producing antibodies to fight infections and provide long-term immunity. B-cell lymphomas include both Hodgkin's lymphomas and most non-Hodgkin's lymphomas.

Prior to this research, the main theory to explain the origins of lymphoma was the malfunction of a mechanism (somatic hypermutation) used by B-cells to modify the genes coding for antibodies. This mechanism is required to produce highly specific antibodies, but it also accidentally alters other genes, leading to lymphoma.

However, the team from the University knew that this theory only accounted for affecting a handful of genes, and the model could only explain certain types of lymphoma.

Led by Dr Thierry Nouspikel, the researchers discovered another mechanism, which potentially affects many more genes and can account for a wider palette of lymphomas. The research found that B-cells actually do not repair the bulk of their DNA and only take care of the few genes they are using. When the B-cells are inert in the blood flow, this is not a problem. However, when they receive a stimulation (e.g. an infection) they start to proliferate and then produce antibodies.

To proliferate they must replicate their DNA, and replication of damaged DNA results in the introduction of mutations, the accumulation of which can lead to lymphoma. Dr Nouspikel's team have designed a novel method to specifically detect such mutations, and have proved that they do occur in genes that have been implicated in lymphoma.

The researchers demonstrated that B-cells are deficient in one of the main DNA repair pathways, known as Nucleotide Excision Repair. This pathway repairs a lot of different DNA lesions, including UV-induced damage and chemical adducts (e.g. from air pollution and cigarette smoke). Their model therefore explains why strong UV exposure (e.g. unprotected sun bathing) is the number one environmental risk factor for lymphoma and also supports the evidence that exposure to air pollution and smoking are also risk factors.

Dr Nouspikel said: "Lymphoma is one of the ten most frequent cancers in adults in the UK, and the third among children. If we want to come up with efficient strategies for prevention and therapy, it is crucial to understand what causes it. The novel mechanism we have discovered potentially accounts for the development of many different types of lymphoma. It may also explain why strong exposure to sunlight is the main environmental risk factor for this cancer."


'/>"/>

Contact: Amy Stone, Media Relations Officer
a.f.stone@sheffield.ac.uk
01-142-221-046
University of Sheffield
Source:Eurekalert

Related medicine news :

1. Embedded Mobile & M2M Device revenues to Rise to Almost $19 Billion Globally by 2014, Says Juniper Research
2. 2010 HSR Impact Award recognizes surgical safety research
3. MSU launches first anti-counterfeiting research program
4. Researchers map all the fragile sites of the yeast Saccharomyces cerevisiaes genome
5. UH Case Medical Center researchers publish promising findings for advanced cervical cancer
6. Researchers discover new way to kill pediatric brain tumors
7. Family Research Council: Planned Parenthood Report Oversexualizes Ten-Year-Olds, Undermines Parental Authority
8. Michael J. Fox Foundation Awards $1 Million to Drive Critical New Research Tools and Technologies in Parkinsons Drug Development
9. Luth Researchs IndicatorEDG(TM) Study Finds Americans Hopes of Achieving Their Dreams Are Fading
10. International Diabetes Federation awards $2 million to 9 global diabetes research projects
11. Gladstones Robert Mahley to receive Research!America advocacy award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... Peter Zipp Insurance, ... and around the greater Phoenix metropolitan region, is announcing a charity event to ... of the Homeless Youth Connection is to promote community awareness of the ongoing ...
(Date:12/8/2016)... ... , ... The Compretta Insurance Agency, a family owned insurance and financial consultation ... County area, is announcing the launch of a charity effort aimed at raising funds ... Pantry has worked for more than 30 years to meet the food needs of ...
(Date:12/8/2016)... ... 08, 2016 , ... Bill Mull Agencies, a Wichita-based firm ... around central Kansas, is joining the Youth Horizons organization for a charity event ... in Wichita, Youth Horizons works to empower area children from unstable, troubled, or ...
(Date:12/7/2016)... ... 07, 2016 , ... Students attending Envision’s summer 2017 ... get hands-on experience in an emergency medical simulation, When Care is Hours Away. ... real-life medical skills that are critical success in a future career and beyond. ...
(Date:12/7/2016)... Wisconsin (PRWEB) , ... December 07, 2016 , ... Kenall ... extraordinary new MedMaster™ MPCNGX . The MPCNGX is a multi-function, sealed, LED luminaire ... right amount of light where and when it’s needed. , A 2’ ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , 8 de dezembro de 2016  A Mederi Therapeutics Inc ... Stretta, um tratamento não cirúrgico para a doença do refluxo gastroesofágico (DRGE). ... ... Live Stretta procedure performed and broadcast ... Endoscopy at Wuhan Union Hospital ...
(Date:12/8/2016)... Dec. 8, 2016 Bodycad announced it ... improving the accuracy, reproducibility and speed for 3D ... and small bone orthopaedic applications. These patents are ... personalized orthopaedic restorations based on each patient,s distinct ... the company harnesses the world,s first suite of ...
(Date:12/8/2016)... Dec. 8, 2016  Valeant Pharmaceuticals International, Inc. ... ("Valeant") today announced positive results from a Phase ... assess the safety and efficacy of IDP-118 (halobetasol ... plaque psoriasis. Within the Phase ... to severe psoriasis, IDP-118 showed statistical significance to ...
Breaking Medicine Technology: